KLEBSIELLA SPP.

PATHOGEN SAFETY DATA SHEET - INFECTIOUS SUBSTANCES

SECTION I - INFECTIOUS AGENT

NAME: Klebsiella spp.

SYNONYM OR CROSS REFERENCE: Human pathogens include K. pneumoniae subspecies pneumoniae, ozaenae, and rhinoscleromatis; K. oxytoca; K. granulomatis; K. variicola; and K. singaporensis. K. planticola, K. terrigena, and K. orinthinolytica have been transferred to the genus Raoultella ^(1-3). K. pnuemoniae was formerly known as Friedlander’s bacillus. K. granulomatis was previously known as Calymmatobacterium granulomatis. K. trevisanii, initially named in 1983, has been established as a heterotypic synonym for R. planticola and, therefore, is no longer recognized. K. mobilis (previously K. aerogenes) previously known as Enterobacter aerogenes is not confirmed as belonging to the genus Klebsiella and as such has been removed from the genus ^{(1, 3)}.

CHARACTERISTICS: Klebsiella spp. are Gram-negative, nonmotile, usually encapsulated rod-shaped bacteria, belonging to the family Enterobacteriaceae ^{(1, 2)}. These bacteria produce lysine decarboxylase but not ornithine decarboxylase and are generally positive in the Voges-Proskauer test. Members of the Enterobacteriaceae family are generally facultatively anaerobic, and range from 0.3 to 1.0 mm in width and 0.6 to 6.0 mm in length ⁽²⁾. Klebsiella spp. often occur in mucoid colonies ^{(1, 2)}. The genus consists of 77 capsular antigens (K antigens), leading to different serogroups.

SECTION II - HAZARD IDENTIFICATION

PATHOGENICITY/TOXICITY: Klebsiella spp. have been identified as important common pathogens for nosocomial pneumonia (7 to 14% of all cases), septicaemia (4 to 15%), urinary tract infection (UTIs; 6 to 17%), wound infections (2 to 4%), intensive care unit (ICU) infections (4 to 17%), and neonatal septicaemias (3 to 20%) ⁽¹⁾. Klebsiella spp. can also cause bacteremias and hepatic infections, and have been isolated from a number of unusual infection, including endocarditis, primary gas-containing mediastinal abscess, peritonitis, acute cholecystitis, crepitant myonecrosis, pyomyositis, necrotizing fasciitis, psoas muscle abscess, fascial space infections of the head and neck, and septic arthritis ⁽¹⁾. They are also important opportunistic pathogens, particularly among the immunocompromised. Pathogenicity factors of Klebsiella spp. include adhesins, siderophores, capsular polysaccharides (CPLs), cell surface lipopolysaccharides (LPSs), and toxins, each of which plays a specific role in the pathogenesis of these species. Depending on the type of infection and the mode of infectivity, cells of Klebsiella spp. may adhere and attack upper respiratory tract epithelial cells, cells in gastrointestinal tract, endothelial cells, or uroepithelial cells, followed by colonization of mucosal membranes. Common underlying conditions include alcoholism, diabetes mellitus, chronic liver disease (cirrhosis), chronic renal failure, cancer, transplants, burns, and/or use of catheters ⁽¹⁾.

Respiratory disease:

K. pnuemoniae – a leading cause of community-acquired and nosocomial pneumonia and lung abscesses. Infection of the upper lobe is more common. Symptoms include: fevers, chills, and leukocytosis with red currant jelly-like sputum ⁽¹⁾. Rare complications include lung infection involving necrosis and sloughing of the entire lobe.

K. ozaenae – causes ozena, a primary atrophic rhinitis (AR) which involves chronic inflammation of the nose ⁽¹⁾.

K. rhinoscleromatis – causes rhinoscleroma (RS), a chronic granulomatous infection which predominantly affects the cavity of the nose ⁽¹⁾.

Central nervous system (CNS) infections:

K. pneumoniae and K. oxytoca – cause community-acquired meningitis and brain abscesses. Clinical symptoms include: headaches, fever, altered conciousness, seizures, and septic shock ⁽¹⁾.

K. ozaenae – associated with rare cases of cerebral abscess and meningitis ⁽¹⁾.

UTIs:

Klebsiella spp. are a frequent cause of UTIs. Significant bacteriuria has been ascribed to K. ozaenae ⁽¹⁾.

Hepatic disease:

K. pnuemoniae – an important causative pathogen for pyogenic liver abscesses with symptoms including fever, right-upper-quadrant pain, nausea, vomiting, diarrhoea or abdominal pain, and leukocytosis. Abscesses occur predominantly in the right lobe and are solitary.

Other infections:

K. granulomatis – causes donovanosis or granuloma, a chronic ulcerative disease that primarily affects the genitalia ⁽¹⁾. Symptoms include development of small papule or ulcer at the site of inoculation that later develop into large red ulcers (lesions) that extend along the moist folds of the genitalia ⁽¹⁾.

EPIDEMIOLOGY: Klebsiella spp. occur worldwide, particularly in tropical and subtropical regions, and are ubiquitous, including forest environments, vegetation soil, water, and mucosal membranes of host species ⁽¹⁾. Although they are common pathogens for community-acquired pneumonias and bacteremias, the majority of the infections are nosocomial (hospital-acquired; ~56% of all Klebsiella infections). Klebsiella spp. are considered endemic in neonatal wards and nosocomial outbreaks, particularly in neonatal wards, are common. Adult males are more susceptible to infection with Klebsiella spp. than adult females ⁽¹⁾; however, Klebsiella spp. demonstrate higher colonization rates among neonates that may survive up to months as compared to a few days to weeks in adults. Risk of infection and carriage rates of Klebsiella spp. increases with increase in duration of stay within a hospital; 11% to 42% increase in carriage rate within 14 days of hospitalization according to one study ⁽¹⁾. Infection and carriage rates also increase with antimicrobial use; this usually leads to the development of extended-spectrum beta-lactamase (ESBLs) which provide resistance against antibiotics ^{(1, 4)}.

K. pneumoniae is most pathogenic to humans among all Klebsiella spp., followed by K. oxytoca. K. ozaenae and K. rhinoscleromatis cause specific diseases in humans ⁽⁴⁾. K. granulomatis and K. variicola have also been indentified as being pathogenic to humans. K. singaporensis is still very novel and its pathogenicity to humans has yet to be determined. Although, the number of infections is lower than some other pathogens, infections by Klebsiella spp. demonstrate substantial morbidity and mortality. K. pneumoniae occurs in the nasopharynx and intestinal tract of humans, as a saprophyte ⁽⁴⁾. It is one of the leading causes of community-acquired pneumonia. It is important cause of primary liver abscess and of microbial fascial space infections among diabetic patients in Asia, predominantly in Taiwan ⁽¹⁾. It is commonly isolated from infections of burns and human bites. Recently, it has become an increasing cause of chronic diarrhoea in HIV infected adults in Africa. K. pnuemoniae and K. oxytoca are important causative agents of community-acquired meningitis and brain abscesses in Asia, predominantly in Taiwan. According to some reports, Klebsiella spp. are responsible for 16 to 43% of central nervous system (CNS) infections and brain abscesses. Environmental strains of K. pneumoniae have been shown to be equally virulent as clinical strains; however, whether this is true or not for other Klebsiella spp. has yet to be determined ⁽⁵⁾.

HOST RANGE: Humans ^{(1, 2)}, mammals ⁽¹⁾ (including horses, bovines, rhesus and squirrel monkeys, guinea pigs, muskrats, lemurs, and bats), aquatic animals (including elephant seals, California sea lions, and harbour seals), reptiles (including snakes, crocodiles, and American alligators), birds, insects, and plants (banana, rice sugar cane and maize) ^{(1, 2)}. Specifically identified sources for some Klebsiella spp. are listed below:

K. pneumoniae – humans, horses, bovines, raptors, and common in all Australian mammals ⁽¹⁾.

K. oxytoca – humans, mammals (ringtail possums, gliders, and bats) throughout Australia, and insects ⁽¹⁾.

K. variicola – humans and plants ^{(1, 2)}.

INFECTIOUS DOSE: Unknown. According to one source, 10⁸ Klebsiella organisms per gram of feces are required to produce damage ⁽¹⁾.

MODE OF TRANSMISSION: Klebsiella spp. can be transmitted through skin contact with environmentally contaminated surfaces and/or objects ⁽¹⁾; examples include Loofah sponges ⁽¹⁾, medical equipment ⁽⁴⁾, and blood products. Fecal transmission has also been suggested for some cases of bacteremia caused by Klebsiella spp. ⁽¹⁾.

K. rhinoscleromatis can be transmitted from person-to-person via airborne secretions; however, prolonged contact with infected individuals is required for infection ⁽¹⁾.

K. granulomatis are sexually transmitted. They may also be vertically transmitted (from mother to child) or by accidental inoculation. Transmission rates between partners are low (<50%) compared to other sexually transmitted diseases.

INCUBATION PERIOD: Not clearly understood. According to some sources, the incubation period for K. granulomatis is usually 1 to 6 weeks ⁽¹⁾.

COMMUNICABILITY: Members of Klebsiella spp. can be transmitted from person-to-person; however, the communicability period is unknown. Approximately one-third of people carry Klebsiellae in their stools ⁽¹⁾; detection rates according to different studies vary from 5% to 36% ⁽⁴⁾. Detection rates in nasopharynx vary from 1% to 6%. Hospital personnel have been shown to frequently carry Klebsiellae on their hands ⁽¹⁾.

SECTION III - DISSEMINATION

RESERVOIR: Infected humans (with or without symptoms of disease) are the primary reservoir for Klebsiella spp ^{(1, 2, 4)}. Other sources include: infected infants (usually asymptomatic) colonized with invasive strains of Klebsiella spp. ⁽¹⁾, hospital patients (for nosocomial infections), and certain plants ⁽⁶⁾.

ZOONOSIS: None.

VECTORS: None.

SECTION IV – STABILITY AND VIABILITY

DRUG SUSCEPTIBILITY: Klebsiella spp. are known to show resistance to penicillins, especially ampicillin and carbenicillin ⁽¹⁾. Since more and more strains of Klebsiella spp. appear to be developing and harbouring extended-spectrum beta-lactamases (ESBLs), cephalosporinases, and carbapenemases, resistance of Klebsiella spp. to current antibiotics appears to be increasing ^{(1, 2, 4)}. According to results from some studies in Europe and USA, ranges of susceptibility were as follows ⁽¹⁾: ceftazidime (92-95%), ceftriaxone (96-98%), cefotaxime (96%), piperacillin-tazobactam (90-97%), imipeneum (98-100%), gentamicin (95-96%), amikacin (98-99%), triethoprimsulfamethoxazole (SXT) (88-90%). Resistance values tend to be higher for strains isolated from ICU patients compared to non-ICU patients. Pan-resistant isolates have been identified in the Indian subcontinent ⁽⁷⁾.

SUSCEPTIBILITY TO DISINFECTANTS: Gram-negative bacteria are generally susceptible to a number of disinfectants, including phenolic compounds, hypochlorites (1% sodium hypochlorite), alcohols (70% ethanol), formaldehyde (18.5 g/L; 5% formalin in water), glutaraldehyde, and iodines (0.075 g/L) ⁽⁸⁾.

PHYSICAL INACTIVATION: Reduction in the growth and metabolic activity of K. pneumoniae at temperatures >35 °C has been reported ⁽⁹⁾. Significant growth reduction has been demonstrated at 60 °C; however, the bacteria still show some metabolic activity (i.e. not completely inactivated). Bacteria are also sensitive to moist heat and dry heat ⁽¹⁰⁾.

SURVIVAL OUTSIDE HOST: Klebsiella spp. grow rapidly on surfaces of potatoes and lettuce with counts exceeding 10³ organisms per g of surface ⁽¹⁾. They have been found in Loofah sponges made from vegetable gourds. They also survive well within wood and sawdust. They do not grow well on human skin and generally exists in infected individuals and/or surfaces, and the environment; surface water, sewage, soil, and on plants, where they can survive for extended periods of time ⁽⁴⁾.

SECTION V - FIRST AID / MEDICAL

SURVEILLANCE: Monitor for symptoms. Other tests include isolating strains of the bacteria or typing different isolates. This is often necessary for investigation of endemic and epidemic nosocomial infections and also for epidemiological investigations from the environment ^{(1, 4)}. Klebsiellae can be isolated by growth in media. Although there are specific chromogenic media available for isolating these bacteria from specific samples, Klebsiellae grow well on blood and non-differential media ⁽¹⁾. Biotyping and serotyping are two common forms of typing methods used for typing Klebsiella spp. ^{(1, 4)}. Serotyping is the most widely used technique for typing these bacteria which involves detection of capsular antigens by means of antisera. Serotyping tests include: quelling reaction, immunofluorescence, double-diffusion gel precipitation, counter-current immunoelectrophoreses, Staphylococcus coagulation, and latex coagulation methods ⁽¹⁾. Biotyping is not preferred due to the large number of reactions and the amount of time required to complete these tests ^{(1, 4)}. Molecular typing methods are also being developed, although they are not commonly used. These include: plasmid analysis, ribotyping, PFGE, and random amplified polymorphic DNA analysis, all of which have been successfully used to track strains epidemiologically ⁽¹⁾.

Note: All diagnostic methods are not necessarily available in all countries.

FIRST AID/TREATMENT: Administer appropriate antibiotic therapy where necessary ^{(1, 2)}.

IMMUNIZATION: None.

PROPHYLAXIS: None.

SECTION VI - LABORATORY HAZARD

LABORATORY-ACQUIRED INFECTIONS: 1 case of laboratory-acquired infection with K. pneumoniae up to 1976 has been reported ⁽¹¹⁾.

SOURCES/SPECIMENS: Sources for clinical samples of Klebsiella spp. primarily include samples from respiratory tract (RT; nasopharyngeal samples) and urinary tract (UT) ^{(1, 2)}. Specific sources identified include ⁽²⁾:

K. pneumoniae – all sites within the human body, RT and UT most common

K. ozaenae – nasal discharge most common, RT, UT, and blood

K. rhinoscleromatis – nasal discharge

K. oxycota – all sites within the human body

K. granulomatis – genital tract

K. variicola – blood, banana plants ⁽¹⁾, rice, sugar cane, and maize

K. singaporensis­ – soil (from roots of sugar cane) ^{(1, 12)}

PRIMARY HAZARDS: Direct contact of mucosal membranes with contaminated surfaces and/or object, and inhalation of infectious airborne secretions, accidental parenteral inoculation and/or ingestion.

SPECIAL HAZARDS: None.

SECTION VII - EXPOSURE CONTROLS / PERSONAL PROTECTION

RISK GROUP CLASSIFICATION: Risk Group 2 ⁽¹³⁾. The risk group associated with “Klebsiella spp.” reflects the genus as a whole, but does not necessarily reflect the risk group classification of every species within the genus.

CONTAINMENT REQUIREMENTS: Containment Level 2 facilities, equipment, and operational practices for work involving infectious or potentially infectious materials, animals, or cultures ⁽¹⁴⁾. The containment and operational requirements may vary with the species, subspecies, and/or strains.

PROTECTIVE CLOTHING: Lab coat. Gloves when direct skin contact with infected materials or animals is unavoidable. Eye protection must be used where there is a known or potential risk of exposure to splashes ⁽¹⁴⁾.

OTHER PRECAUTIONS: All procedures that may produce aerosols, or involve high concentrations or large volumes should be conducted in a biological safety cabinet (BSC). The use of needles, syringes, and other sharp objects should be strictly limited. Additional precautions should be considered with work involving animals or large scale activities ⁽¹⁴⁾.

SECTION VIII - HANDLING AND STORAGE

SPILLS: Allow aerosols to settle and, wearing protective clothing, gently cover spill with paper towels and apply appropriate disinfectant, starting at the perimeter and working towards the centre. Allow sufficient contact time before clean up ⁽¹⁴⁾.

DISPOSAL: Decontaminate all wastes that contain or have come in contact with the infectious organism before disposing by autoclave, chemical disinfection, gamma irradiation, or incineration ⁽¹⁴⁾.

STORAGE: The infectious agent should be stored in leak-proof containers that are appropriately labelled ⁽¹⁴⁾.

SECTION IX - REGULATORY AND OTHER INFORMATION

REGULATORY INFORMATION: The import, transport, and use of pathogens in Canada is regulated under many regulatory bodies, including the Public Health Agency of Canada, Health Canada, Canadian Food Inspection Agency, Environment Canada, and Transport Canada. Users are responsible for ensuring they are compliant with all relevant acts, regulations, guidelines, and standards.

UPDATED: September 2011

PREPARED BY: Pathogen Regulation Directorate, Public Health Agency of Canada.

Although the information, opinions and recommendations contained in this Pathogen Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date.

Copyright ©

Public Health Agency of Canada, 2011

Canada

REFERENCES:

1. Janda, J. M., & Abbott, S. L. (2006). The Genera Klebsiella and Raoultella. The Enterobacteria (2nd ed., pp. 115-129). Washington, USA: ASM Press.
   
   
2. Abbott, S. L. (2007). Klebsiella, Enterobacter, Citrobacter, Serratia, Plesiomonas, and Other Enterobacteriaceae. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry & M. A. Pfaller (Eds.), Manual of Clinical Microbiology (9th ed., pp. 698-711). Washington, USA: ASM Press.
   
   
3. Euzéby, J. P. (2010). List of Bacterial Names with Standing in Nomenclature. Int. J. Syst. Bacteriol., 47, 13 July, 2010. Retrieved from http://www.bacterio.cict.fr/m/micrococcus.html
   
   
4. Podschun, R., & Ullmann, U. (1998). Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clinical Microbiology Reviews, 11(4), 589-603.
   
   
5. Podschun, R., Pietsch, S., Holler, C., & Ullmann, U. (2001). Incidence of Klebsiella species in surface waters and their expression of virulence factors. Applied and Environmental Microbiology, 67(7), 3325-3327. doi:10.1128/AEM.67.7.3325-3327.2001
   
   
6. Rosenblueth, M., Martinez, L., Silva, J., & Martinez-Romero, E. (2004). Klebsiella variicola, a novel species with clinical and plant-associated isolates. Systematic and Applied Microbiology, 27(1), 27-35.
   
   
7. Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., Irfan, S., Krishnan, P., Kumar, A. V., Maharjan, S., Mushtaq, S., Noorie, T., Paterson, D. L., Pearson, A., Perry, C., Pike, R., Rao, B., Ray, U., Sarma, J. B., Sharma, M., Sheridan, E., Thirunarayan, M. A., Turton, J., Upadhyay, S., Warner, M., Welfare, W., Livermore, D. M., & Woodford, N. (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet Infectious Diseases, 10(9), 597-602. doi:10.1016/S1473-3099(10)70143-2
   
   
8. Disinfection and Sterilization. (1993). Laboratory Biosafety Manual (2nd ed., pp. 60-70). Geneva: WHO.
   
   
9. Mason, C. A., & Hamer, G. (1987). Survival and activity of Klebsiella pneumoniae at super-optimal temperatures. Bioprocess and Biosystems Engineering, 2(3), 121-127.
   
   
10. Joslyn, L. J. (2000). Sterilization by Heat. In S. S. Block (Ed.), Disinfection, Sterilization, and Preservation (5th ed., pp. 695-728). Philadelphia, USA: Lippincott Williams & Wilkins.
    
    
11. Pike, R. M. (1976). Laboratory associated infections: summary and analysis of 3921 cases. Health Laboratory Science, 13(2), 105-114.
    
    
12. Li, X., Zhang, D., Chen, F., Ma, J., Dong, Y., & Zhang, L. (2004). Klebsiella singaporensis sp. nov., a novel isomaltulose-producing bacterium. International Journal of Systematic and Evolutionary Microbiology, 54(Pt 6), 2131-2136. doi:10.1099/ijs.0.02690-0
    
    
13. Human Pathogens and Toxins Act. S.C. 2009, c. 24. Government of Canada, Second Session, Fortieth Parliament, 57-58 Elizabeth II, 2009, (2009).
    
    
14. Public Health Agency of Canada. (2004). In Best M., Graham M. L., Leitner R., Ouellette M. and Ugwu K. (Eds.), Laboratory Biosafety Guidelines (3rd ed.). Canada: Public Health Agency of Canada.